Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Clin Gastroenterol Hepatol. 2023 Sep;21(10):2560-2569.e15. doi: 10.1016/j.cgh.2022.09.028. Epub 2022 Oct 3.
Metabolic associated fatty liver disease (MAFLD) was recently proposed as an alternative name change for better encapsulation of disease. However, there exists a spectrum of MAFLD where both metabolically healthy (MH) and metabolically unhealthy (MU) individuals are included. In view of limited evidence, we sought to examine the prevalence, clinical characteristics, and differences in outcomes of MH-MAFLD at the population level.
Data were used from the United States National Health and Nutrition Examination Survey 1999 to 2018. Multivariate logistic regression analysis was used to obtain odds ratios for the estimation of events. Survival analysis was conducted with Cox regression and the Fine-Gray subdistribution model.
There were 32,683 overweight and obese individuals included in the analysis. In MAFLD patients, the prevalence of MH-MAFLD was 6.92% (95% confidence interval [CI], 6.58%-7.27%), and 93.08% (95% CI, 92.73%-93.42%) were considered as MU-MAFLD. Multivariate analysis found a significantly higher risk of MACE (odds ratio, 1.38; 95% CI, 1.28-1.49; P < .01), all-cause (hazard ratio, 1.24; 95% CI, 1.17-1.32; P < .01), cardiovascular disease (SHR, 1.20; 95% CI, 1.02-1.42; P = .03), and cancer mortality (SHR, 1.24; 95% CI, 1.07-1.44; P < .01) in MU-MAFLD relative to non-MAFLD. However, MH-MAFLD individuals were not associated with a statistically significant increased risk of these adverse outcomes compared with non-MAFLD. MU-MAFLD diabetics were also at a higher risk of adverse events compared with non-diabetics.
This study reports on the heterogeneity and spectrum of metabolic dysfunction that exists in overweight and obese MAFLD. Although MAFLD may potentially be advantageous in improving awareness and patient outcomes, there remains substantial heterogeneity within patients included in MAFLD on the basis of the underlying metabolic burden.
代谢相关脂肪性肝病(MAFLD)最近被提议作为一个更好的疾病概括的替代名称变更。然而,在 MAFLD 中存在一个谱,其中包括代谢健康(MH)和代谢不健康(MU)个体。鉴于证据有限,我们试图在人群水平上检查 MH-MAFLD 的患病率、临床特征和结局差异。
使用了美国 1999 年至 2018 年国家健康和营养检查调查的数据。多变量逻辑回归分析用于估计事件的优势比。采用 Cox 回归和 Fine-Gray 亚分布模型进行生存分析。
分析中纳入了 32683 名超重和肥胖个体。在 MAFLD 患者中,MH-MAFLD 的患病率为 6.92%(95%置信区间[CI],6.58%-7.27%),93.08%(95%CI,92.73%-93.42%)被认为是 MU-MAFLD。多变量分析发现,MACE(比值比,1.38;95%CI,1.28-1.49;P<.01)、全因(风险比,1.24;95%CI,1.17-1.32;P<.01)、心血管疾病(SHR,1.20;95%CI,1.02-1.42;P=0.03)和癌症死亡率(SHR,1.24;95%CI,1.07-1.44;P<.01)的风险显著增加。然而,与非 MAFLD 相比,MU-MAFLD 个体与这些不良结局的风险增加无统计学意义相关。与非糖尿病患者相比,MU-MAFLD 糖尿病患者的不良事件风险也更高。
本研究报告了超重和肥胖 MAFLD 中存在的代谢功能障碍的异质性和谱。尽管 MAFLD 可能在提高意识和改善患者结局方面具有优势,但根据潜在的代谢负担,MAFLD 患者中仍存在相当大的异质性。